Taro Pharmaceutical Industries Ltd (NYSE:TARO)
| 74.19 Delayed Data As of May 14 |  +0.24 / +0.32%Today’s Change | 53.95 Today|||52-Week Range 80.00 | +1.05% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Generic | MARKET CAP $3.0B |
Company Description
Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.
Contact Information
Taro Pharmaceutical Industries Ltd. 14 Hakitor Street Haifa Bay Haifa 2624761 |
Employees
Shareholders
| Other institutional | 7.48% |
| Mutual fund holders | 5.89% |
| Individual stakeholders | 11.85% |
Top Executives
| Uday Vijaykumar Baldota | Chief Executive Officer & Director |
| Itamar Karsenti | Vice President & Head-Operations |
| Daphne Yan Huang | VP, Chief Financial & Accounting Officer |
| Avi Avramoff | Vice President & Head-Research & Development |
| Richard Glaze | Vice President & Head-Information Technology |
